NCT05904717View on ClinicalTrials.gov

Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

January 31, 2026

Conditions
REM Sleep Behavior Disorder
Interventions
DRUG

PXS-4728 (A)

Participants will receive once daily (QD) for period of 12 weeks

DRUG

Matching Placebo (B)

Participants will receive once daily (QD) for period of 12 weeks

Trial Locations (3)

2050

Cognitive Neuroscience Brain & Mind Centre, Camperdown

2109

Parkinsons Disease Research Clinic - Macquarie University, Macquarie

Unknown

Clinical Neuroscience Nuffield Department of Clinical Neurosciences, Oxford

Sponsors

Lead Sponsor

Syntara
All Listed Sponsors
lead

Syntara

INDUSTRY

NCT05904717 - Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder | Biotech Hunter | Biotech Hunter